

# Jeffrey L Anderson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2790213/publications.pdf>

Version: 2024-02-01

132  
papers

13,340  
citations

81434

41  
h-index

25230

113  
g-index

133  
all docs

133  
docs citations

133  
times ranked

22780  
citing authors

#	ARTICLE	IF	CITATIONS
1	Spectrum of radionuclide perfusion study abnormalities in takotsubo cardiomyopathy. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 1034-1046.	1.4	6
2	Association of periodic fasting lifestyles with survival and incident major adverse cardiovascular events in patients undergoing cardiac catheterization. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1774-1781.	0.8	17
3	Behavioral Nudges as Patient Decision Support for Medication Adherence: The ENCOURAGE Randomized Controlled Trial. <i>American Heart Journal</i> , 2022, 244, 125-134.	1.2	16
4	Economics and outcomes of sotalol inpatient dosing approaches in patients with atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 333-342.	0.8	11
5	Association of Rhesus Factor Blood Type with Risk of SARS-CoV-2 Infection and COVID-19 Severity. <i>British Journal of Haematology</i> , 2022, , .	1.2	5
6	Intermittent fasting and changes in Galectin-3: A secondary analysis of a randomized controlled trial of disease-free subjects. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1538-1548.	1.1	8
7	A Small but Significantly Greater Incidence of Inflammatory Heart Disease Identified After Vaccination for Severe Acute Respiratory Syndrome Coronavirus 2. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab663.	0.4	4
8	Coronary Artery Calcium Versus Pooled Cohort Equations Score for Primary Prevention Guidance. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 843-855.	2.3	15
9	Association of the Intermountain Risk Score with major adverse health events in patients positive for COVID-19: an observational evaluation of a US cohort. <i>BMJ Open</i> , 2022, 12, e053864.	0.8	1
10	Association of periodic fasting with lower severity of COVID-19 outcomes in the SARS-CoV-2 prevaccine era: an observational cohort from the INSPIRE registry. <i>BMJ Nutrition, Prevention and Health</i> , 2022, 5, 145-153.	1.9	8
11	Evaluation of Treatment With Angiotensin Converting Enzyme Inhibitors and the Risk of Lung Cancer: ERACER—An Observational Cohort Study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 321-327.	1.0	4
12	SARS-CoV-2 as an inflammatory cardiovascular disease: current knowledge and future challenges. <i>Future Cardiology</i> , 2021, 17, 1277-1291.	0.5	9
13	Association of Sociodemographic Factors and Blood Group Type With Risk of COVID-19 in a US Population. <i>JAMA Network Open</i> , 2021, 4, e217429.	2.8	33
14	Depression as a Driving Force for Low Time in Therapeutic Range and Dementia in Patients With and Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 153, 58-64.	0.7	5
15	Simplifying the ISCHEMIA trial algorithm for clinical practice: Identifying left main coronary artery disease using coronary artery calcium scans. <i>American Heart Journal</i> , 2021, 239, 129-134.	1.2	2
16	Absent or Mild Coronary Calcium Predicts Low-Risk Stress Test Results and Outcomes in Patients Considered for Flecainide Therapy. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 648-655.	1.0	0
17	Randomized controlled trial of once-per-week intermittent fasting for health improvement: the WONDERFUL trial. <i>European Heart Journal Open</i> , 2021, 1, .	0.9	17
18	Preferential Metabolic Improvement by Intermittent Fasting in People with Elevated Baseline Red Cell Distribution Width: A Secondary Analysis of the WONDERFUL Randomized Controlled Trial. <i>Nutrients</i> , 2021, 13, 4407.	1.7	3

#	ARTICLE	IF	CITATIONS
19	Free thyroxine within the normal reference range predicts risk of atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 18-29.	0.8	12
20	Comparison of Three Atherosclerotic Cardiovascular Disease Risk Scores With and Without Coronary Calcium for Predicting Revascularization and Major Adverse Coronary Events in Symptomatic Patients Undergoing Positron Emission Tomography-Stress Testing. <i>American Journal of Cardiology</i> , 2020, 125, 341-348.	0.7	9
21	Feasibility of combining serial smartphone single-lead electrocardiograms for the diagnosis of ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2020, 221, 125-135.	1.2	22
22	Discovery of TITIN Gene Truncating Variant Mutations and 5-Year Outcomes in Patients With Nonischemic Dilated Cardiomyopathy. <i>American Journal of Cardiology</i> , 2020, 137, 97-102.	0.7	8
23	Smartphone 12-lead ECG—Exciting but must be handled with care. <i>American Heart Journal</i> , 2020, 226, 269.	1.2	2
24	Limited Evidence for the Health Effects and Safety of Intermittent Fasting Among Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 341.	3.8	41
25	Intermountain chronic disease risk score (ICHRON) validation for prediction of incident chronic disease diagnoses in an australian primary prevention population. <i>European Journal of Internal Medicine</i> , 2020, 79, 81-87.	1.0	2
26	Absence of Coronary Artery Calcium During Positron Emission Tomography Stress Testing in Patients Without Known Coronary Artery Disease Identifies Individuals With Very Low Risk of Cardiac Events. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e009907.	1.3	12
27	World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI. <i>Global Heart</i> , 2020, 9, 457.	0.9	34
28	Abstract 13551: Identifying Left Main Coronary Artery Disease Using Coronary Artery Calcium Scans. <i>Circulation</i> , 2020, 142, .	1.6	0
29	Abstract 14607: Randomized Controlled Trial of Once-Per-Week Intermittent Fasting for the Reduction of Low-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2020, 142, .	1.6	0
30	Abstract 16802: Economics and Outcomes of Sotalol and Dofetilide In-Patient Dosing Approaches in Patients With Atrial Fibrillation. <i>Circulation</i> , 2020, 142, .	1.6	0
31	Abstract 13889: The Influence of Depression on Dementia Risk in Patients With Atrial Fibrillation. <i>Circulation</i> , 2020, 142, .	1.6	0
32	Patterns of cardiac dysfunction after carbon monoxide poisoning. <i>Undersea and Hyperbaric Medicine</i> , 2020, 47, 477-485.	0.1	0
33	Circulating Levels of Biomarkers of Cerebral Injury in Patients with Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 124, 1697-1700.	0.7	11
34	Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 834.	3.8	9
35	Pilot Study of Novel Intermittent Fasting Effects on Metabolomic and Trimethylamine N-oxide Changes During 24-hour Water-Only Fasting in the FEELGOOD Trial. <i>Nutrients</i> , 2019, 11, 246.	1.7	35
36	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002470.	1.6	17

#	ARTICLE	IF	CITATIONS
37	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002471.	1.6	22
38	Safety and Efficacy of Periprocedural Heparin Plus a Short-Term Infusion of Tirofiban Versus Bivalirudin Monotherapy in Patients Who Underwent Percutaneous Coronary Intervention (from the Tj ETQq0 0 0 ggBT /Overlock 10 Tf 1927-1934.	0.7	2
39	CHA2DS2-VASc scores and Intermountain Mortality Risk Scores for the joint risk stratification of dementia among patients with atrial fibrillation. <i>Heart Rhythm</i> , 2019, 16, 3-9.	0.3	23
40	Prediction of Long-Term Incidence of Chronic Cardiovascular and Cardiopulmonary Diseases in Primary Care Patients for Population Health Monitoring: The Intermountain Chronic Disease Model (ICHRON). <i>Mayo Clinic Proceedings</i> , 2019, 94, 1221-1230.	1.4	7
41	Practical laboratory-based clinical decision tools and associations with short-term bleeding and mortality outcomes. <i>Clinica Chimica Acta</i> , 2018, 482, 166-171.	0.5	0
42	Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease—Real-world experience within a large integrated health care system: The IMPRES study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1008-1018.e1.	0.6	8
43	GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study. <i>American Heart Journal</i> , 2018, 202, 27-32.	1.2	26
44	Smartphone ECG for evaluation of ST-segment elevation myocardial infarction (STEMI): Design of the ST LEUIS International Multicenter Study. <i>Journal of Electrocardiology</i> , 2018, 51, 260-264.	0.4	21
45	Improving CHA <sub>2</sub> DS <sub>2</sub> -VASc stratification of non-fatal stroke and mortality risk using the Intermountain Mortality Risk Score among patients with atrial fibrillation. <i>Open Heart</i> , 2018, 5, e000907.	0.9	16
46	Extreme erythrocyte macrocytic and microcytic percentages are highly predictive of morbidity and mortality. <i>JCI Insight</i> , 2018, 3, .	2.3	10
47	Implementation of a cardiac PET stress program: comparison of outcomes to the preceding SPECT era. <i>JCI Insight</i> , 2018, 3, .	2.3	12
48	Assessing the Risks Associated with MRI in Patients with a Pacemaker or Defibrillator. <i>New England Journal of Medicine</i> , 2017, 376, 755-764.	13.9	308
49	The association of antidepressant and statin use with death and incident cardiovascular disease varies by depression severity. <i>Psychology, Health and Medicine</i> , 2017, 22, 919-931.	1.3	6
50	Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2017, 376, 2053-2064.	13.9	761
51	Real world MRI experience with nonconditional and conditional cardiac rhythm devices after MagnaSafe. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 1468-1474.	0.8	14
52	Circulating Thyroxine. <i>Circulation Research</i> , 2017, 121, 1304-1306.	2.0	1
53	Improving secondary cardiovascular risk prediction: taking a few steps along the long path from probability toward certainty. <i>European Heart Journal</i> , 2017, 38, 3219-3221.	1.0	4
54	β <sub>2</sub> -blocker dosage and outcomes after acute coronary syndrome. <i>American Heart Journal</i> , 2017, 184, 26-36.	1.2	19

#	ARTICLE	IF	CITATIONS
55	Utility of high density lipoprotein particle concentration in predicting future major adverse cardiovascular events among patients undergoing angiography. <i>Clinical Biochemistry</i> , 2016, 49, 1122-1126.	0.8	8
56	The Impact of Age on 5-Year Outcomes After Atrial Fibrillation Catheter Ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 141-146.	0.8	68
57	Impact of Testosterone Replacement Therapy on Myocardial Infarction, Stroke, and Death in Men With Low Testosterone Concentrations in an Integrated Health Care System. <i>American Journal of Cardiology</i> , 2016, 117, 794-799.	0.7	113
58	The utility of the apolipoprotein A1 remnant ratio in predicting incidence coronary heart disease in a primary prevention cohort: The Jackson Heart Study. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 769-776.	0.8	4
59	Shortened telomere length is associated with paroxysmal atrial fibrillation among cardiovascular patients enrolled in the Intermountain Heart Collaborative Study. <i>Heart Rhythm</i> , 2016, 13, 21-27.	0.3	38
60	Short-Term Exposure to Fine Particulate Matter Air Pollution Is Preferentially Associated With the Risk of ST-Segment Elevation Acute Coronary Events. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	99
61	Haptoglobin 2-2 Genotyping for Refining Standard Cardiovascular Risk Assessment. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1800-1802.	1.2	1
62	Percent Time With a Supratherapeutic INR in Atrial Fibrillation Patients Also Using an Antiplatelet Agent Is Associated With Long-Term Risk of Dementia. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 1180-1186.	0.8	40
63	The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation. <i>Heart Rhythm</i> , 2015, 12, 681-686.	0.3	72
64	Five-Year Outcomes of Catheter Ablation in Patients with Atrial Fibrillation and Left Ventricular Systolic Dysfunction. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 363-370.	0.8	63
65	Smartphone ECG for evaluation of STEMI: Results of the ST LEUIS Pilot Study. <i>Journal of Electrocardiology</i> , 2015, 48, 249-259.	0.4	80
66	Evolution of the ACC/AHA Clinical Practice Guidelines in Perspective. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2735-2738.	1.2	19
67	Health effects of intermittent fasting: hormesis or harm? A systematic review. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 464-470.	2.2	183
68	Complete blood count risk score and its components, including RDW, are associated with mortality in the JUPITER trial. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 519-526.	0.8	41
69	Pulmonary-Specific Intermountain Risk Score Predicts All-Cause Mortality via Spirometry, the Red Cell Distribution Width, and Other Laboratory Parameters. <i>Respiratory Care</i> , 2015, 60, 1314-1323.	0.8	10
70	Letter by Horne et al Regarding Article, "Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Survey III (NHANES-III)". <i>Circulation</i> , 2015, 131, e472.	1.6	5
71	Association of the dispersion in red blood cell volume with mortality. <i>European Journal of Clinical Investigation</i> , 2015, 45, 541-549.	1.7	16
72	Long-Term Natural History of Adult Wolff-Parkinson-White Syndrome Patients Treated With and Without Catheter Ablation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 1465-1471.	2.1	44

#	ARTICLE	IF	CITATIONS
73	Multicenter study of the safety and effects of magnetic resonance imaging in patients with coronary sinus left ventricular pacing leads. <i>Heart Rhythm</i> , 2015, 12, 345-349.	0.3	25
74	HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. <i>European Heart Journal</i> , 2015, 36, 22-30.	1.0	142
75	AHA/ACC/HHS Strategies to Enhance Application of Clinical Practice Guidelines in Patients With Cardiovascular Disease and Comorbid Conditions. <i>Circulation</i> , 2014, 130, 1662-1667.	1.6	132
76	World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. <i>Nature Reviews Cardiology</i> , 2014, 11, 597-606.	6.1	267
77	Clinical Predictors of Risk for Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1498-1505.	1.4	46
78	Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. <i>Heart Rhythm</i> , 2014, 11, 2206-2213.	0.3	130
79	2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. <i>Circulation</i> , 2014, 129, S49-73.	1.6	2,823
80	Hypothyroidism as a risk factor for statin intolerance. <i>Journal of Clinical Lipidology</i> , 2014, 8, 401-407.	0.6	21
81	Validation and Quantification of Genetic Determinants of Lipoprotein-a Levels and Predictive Value for Angiographic Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2013, 112, 799-804.	0.7	14
82	Secretory Phospholipase A2-IIA and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1966-1976.	1.2	115
83	Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 112-112.	1.5	2
84	A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II). <i>Circulation</i> , 2012, 125, 1997-2005.	1.6	217
85	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 453-495.	0.7	157
86	Relation of Routine, Periodic Fasting to Risk of Diabetes Mellitus, and Coronary Artery Disease in Patients Undergoing Coronary Angiography. <i>American Journal of Cardiology</i> , 2012, 109, 1558-1562.	0.7	52
87	Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: Dependent or independent risk factors?. <i>American Heart Journal</i> , 2011, 162, 331-339.e2.	1.2	127
88	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. <i>Nature Genetics</i> , 2011, 43, 333-338.	9.4	1,685
89	Relation of Vitamin D Deficiency to Cardiovascular Risk Factors, Disease Status, and Incident Events in a General Healthcare Population. <i>American Journal of Cardiology</i> , 2010, 106, 963-968.	0.7	571
90	2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. <i>Journal of the American College of Cardiology</i> , 2010, 56, e50-e103.	1.2	1,150

#	ARTICLE	IF	CITATIONS
91	Joint effects of common genetic variants from multiple genes and pathways on the risk of premature coronary artery disease. <i>American Heart Journal</i> , 2010, 160, 250-256.e3.	1.2	29
92	Lack of Association of Tegaserod With Adverse Cardiovascular Outcomes in a Matched Case-Control Study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2009, 14, 170-175.	1.0	37
93	Fasting and Other Health Influences. <i>American Journal of Cardiology</i> , 2009, 103, 1042.	0.7	1
94	Lipoprotein-Associated Phospholipase A2: An Independent Predictor of Coronary Artery Disease Events in Primary and Secondary Prevention. <i>American Journal of Cardiology</i> , 2008, 101, S23-S33.	0.7	74
95	Usefulness of Routine Periodic Fasting to Lower Risk of Coronary Artery Disease in Patients Undergoing Coronary Angiography. <i>American Journal of Cardiology</i> , 2008, 102, 814-819.e1.	0.7	82
96	Genetic variation at the 9p21 locus predicts angiographic coronary artery disease prevalence but not extent and has clinical utility. <i>American Heart Journal</i> , 2008, 156, 1155-1162.e2.	1.2	67
97	Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation. <i>Circulation</i> , 2007, 116, 2563-2570.	1.6	660
98	Usefulness of a Complete Blood Count-Derived Risk Score to Predict Incident Mortality in Patients With Suspected Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2007, 99, 169-174.	0.7	101
99	Do Statins Increase the Risk of Idiopathic Polyneuropathy?. <i>American Journal of Cardiology</i> , 2005, 95, 1097-1099.	0.7	26
100	Atrial dimensions in health and left ventricular disease using cardiovascular magnetic resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2005, 7, 671-5.	1.6	24
101	Which Features of the Metabolic Syndrome Predict the Prevalence and Clinical Outcomes of Angiographic Coronary Artery Disease?. <i>Cardiology</i> , 2004, 101, 185-193.	0.6	53
102	Frequency of elevation of C-reactive protein in atrial fibrillation. <i>American Journal of Cardiology</i> , 2004, 94, 1255-1259.	0.7	134
103	Introduction: NASPE Atrial Fibrillation Supplement 2004. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2004, 10, 5-7.	0.6	0
104	Pharmacogenomics in Cardiovascular Medicine. <i>Drug Development Research</i> , 2004, 62, 180-190.	1.4	3
105	Effect of folic acid fortification of food on homocysteine-related mortality. <i>American Journal of Medicine</i> , 2004, 116, 158-164.	0.6	36
106	Improvements in 1-Year Cardiovascular Clinical Outcomes Associated with a Hospital-Based Discharge Medication Program. <i>Annals of Internal Medicine</i> , 2004, 141, 446.	2.0	118
107	Antibiotic trials for coronary heart disease. <i>Texas Heart Institute Journal</i> , 2004, 31, 33-8.	0.1	19
108	Failure of benefit and early hazard of bucindolol for Class IV heart failure. <i>Journal of Cardiac Failure</i> , 2003, 9, 266-277.	0.7	26

#	ARTICLE	IF	CITATIONS
109	Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2003, 146, 351-358.	1.2	134
110	Cardiovascular Pharmacogenomics: Current Status, Future Prospects. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2003, 8, 71-83.	1.0	34
111	Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. <i>American Journal of Cardiology</i> , 2001, 87, 257-261.	0.7	164
112	Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease. <i>Circulation</i> , 2000, 102, 1755-1760.	1.6	195
113	Clinical Implications of the CAMIAT, EMIAT and SWORD Trials: A North American Perspective. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1998, 2, 30-33.	0.9	0
114	Spontaneous Variability of Ventricular Ectopic Activity in Patients with Sustained Ventricular Tachycardia and in Survivors of Cardiac Arrest. <i>Annals of Noninvasive Electrocardiology</i> , 1998, 3, 194-201.	0.5	0
115	Implementation of a computerized cardiovascular information system in a private hospital setting. <i>American Heart Journal</i> , 1998, 136, 792-803.	1.2	53
116	Infection With <i>Chlamydia pneumoniae</i> Accelerates the Development of Atherosclerosis and Treatment With Azithromycin Prevents It in a Rabbit Model. <i>Circulation</i> , 1998, 97, 633-636.	1.6	488
117	The Total Artificial Heart: From Initial Application to Therapeutic Option. <i>Journal of Interventional Cardiology</i> , 1997, 10, 335-342.	0.5	1
118	Impact of the Food and Drug Administration Approval of Flecainide and Encainide on Coronary Artery Disease Mortality: Putting Deadly Medicine to the Test. <i>American Journal of Cardiology</i> , 1997, 79, 43-47.	0.7	14
119	The TEAM Studies: A Review. <i>Journal of Interventional Cardiology</i> , 1996, 9, 361-372.	0.5	0
120	Contemporary Clinical Trials in Ventricular Tachycardia and Fibrillation: Implications of ESVEM, CASCADE, and CASH for Clinical Management. <i>Journal of Cardiovascular Electrophysiology</i> , 1995, 6, 880-886.	0.8	13
121	Localization of a Gene Responsible for Familial Dilated Cardiomyopathy to Chromosome 1q32. <i>Circulation</i> , 1995, 92, 3387-3389.	1.6	123
122	Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. <i>American Journal of Cardiology</i> , 1994, 74, 578-584.	0.7	46
123	Comparison of Signal-Averaging Electrocardiographic Systems Using Device Specific Criteria in 104 Normal Subjects. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994, 17, 2178-2182.	0.5	8
124	Therapeutic management of acute myocardial infarction. <i>American Journal of Health-System Pharmacy</i> , 1990, 47, S5-S10.	0.5	0
125	Worsening of Ventricular Tachycardia by Amiodarone. <i>Journal of Clinical Pharmacology</i> , 1988, 28, 406-411.	1.0	5
126	The Disposition of Recainam Hydrochloride During and After Intravenous Loading and Maintenance Infusion in Cardiac Patients. <i>Journal of Clinical Pharmacology</i> , 1987, 27, 951-956.	1.0	4



#	ARTICLE	IF	CITATIONS
127	Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: A probable proarrhythmic effect. <i>American Heart Journal</i> , 1987, 113, 1071-1077.	1.2	69
128	Recent Clinical Developments in Thrombolysis in Acute Myocardial Infarction. <i>Drugs</i> , 1987, 33, 22-32.	4.9	2
129	Reperfusion in Acute Myocardial Infarction. <i>Drugs</i> , 1987, 33, 154-162.	4.9	5
130	Flecainide: A New Prototype Antiarrhythmic Agent. <i>Pharmacotherapy</i> , 1985, 5, 209-221.	1.2	19
131	Disposition of Intravenous Pirmenol. <i>Journal of Clinical Pharmacology</i> , 1983, 23, 113-122.	1.0	19
132	Oral Flecainide Acetate for the Treatment of Ventricular Arrhythmias. <i>New England Journal of Medicine</i> , 1981, 305, 473-477.	13.9	233